Impact of KRAS Mutations on Management of Colorectal Carcinoma

@inproceedings{Sullivan2011ImpactOK,
  title={Impact of KRAS Mutations on Management of Colorectal Carcinoma},
  author={Kevin Sullivan and Peter S. Kozuch},
  booktitle={Pathology research international},
  year={2011}
}
The epidermal growth factor receptor (EGFR) pathway is a therapeutic target in the management of colorectal cancer (CRC). EGFR antagonists are active in this disease; however, only a subset of patients respond to such therapy. A Kirsten ras sarcoma viral oncogene (KRAS) wild-type (WT) status of the tumor is necessary, but possibly not sufficient, for a response to anti-EGFR monoclonal antibody therapy. Mechanisms of primary resistance to such therapy in patients harboring KRAS WT tumors are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 102 references

Randomized phase III study of panitumumab with FOLFOX4 compared to FOL- FOX4 alone as first-line treatment for metastatic colorectal cancer: PRIME trial

  • S. Siena, J. Cassidy, J. Tabernero
  • Proceedings of the Gastrointestinal Cancers…
  • 2010
Highly Influential
9 Excerpts

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial

  • E. Van Cutsem, I. Lang, G. Folprecht
  • Proceedings of the Gastrointestinal Cancers…
  • 2010
Highly Influential
4 Excerpts

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial

  • E. Van Cutsem, M. Nowacki, I. Lang
  • Journal of Clinical Oncology, vol. 25, no. 18…
  • 2007
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…